All In Biotech

NDA 214826 · Almatica

Loreev Xr

Lorazepam · Oral · Benzodiazepine

Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 27, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

157

26 Phase 3, 11 recruiting

FAERS reports

132,454

104,627 serious, 20,049 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7 )]. The use of benzodiazepines, including LOREEV XR, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes....

What it is approved for

From the label in effect Oct 8, 2025.

LOREEV XR is indicated for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets. LOREEV XR is a benzodiazepine indicated for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets ( 1 )

Mechanism: Lorazepam exerts its effect for the treatment of anxiety disorders through binding to the benzodiazepine site of the gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • LOREEV XR · LORAZEPAM 3MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • LOREEV XR · LORAZEPAM 1MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • LOREEV XR · LORAZEPAM 1.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • LOREEV XR · LORAZEPAM 2MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lorazepam" as an intervention, any sponsor and status, largest first.

All 157 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,356
  • fatigue9,067
  • nausea8,908
  • off label use7,927
  • diarrhoea7,263
  • dyspnoea6,330
  • vomiting6,047
  • headache5,884
  • dizziness5,685
  • anxiety5,680
  • pain5,632
  • death4,866

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,777
20052,009
20061,920
20071,850
20082,103
20092,447
20103,536
20113,806
20124,683
20133,797
20144,705
20157,017
20167,670
20178,448
201810,305
201910,135
20209,963
20218,953
20228,543
20237,941
20248,189
20257,553
20265,100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Loreev XR (Lorazepam)

2024 spending

$2.2M

Beneficiaries

1,089

4,959 claims

Per beneficiary

$2,064

$14.70 per unit

View as table
YearSpending
2020$0
2021$18,437
2022$663,298
2023$1,474,140
2024$2,247,297

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,059 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.